# Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Source: https://onco.cc/trials/nct06908993/  
OnCo record `nct06908993` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tepotinib, pemetrexed, vinorelbine, docetaxel and other drugs in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, now recruiting.

## Summary

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated is a phase 3, randomised interventional study registered as NCT06908993 by Intergroupe Francophone de Cancerologie Thoracique, with a registry enrolment figure of 133 participants, started 2025-12-09 and due to reach its primary completion in 2028-03-15. Interventions recorded: Tepotinib; Pemetrexed (Alimta); Vinorelbine; Gemcitabine alone; Docetaxel; Paclitaxel; Pembrolizumab; Nivolumab; Atezolizumab. Conditions listed: Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Histologically proven advanced NSCLC". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: COMET
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06908993
- Phase: 3
- Setting: A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Enrolled: 133

## Sources

- ClinicalTrials.gov NCT06908993: https://clinicaltrials.gov/study/NCT06908993

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tepotinib](https://onco.cc/drugs/tepotinib/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06908993.json